Literature DB >> 24771510

Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.

Kwai Fung Hui1, Alan K S Chiang.   

Abstract

The current paradigm stipulates that inhibition of histone deacetylase (HDAC) 6 is essential for the combinatorial effect of proteasome and HDAC inhibitors for the treatment of cancers. Our study aims to investigate the effect of combining different class I HDAC inhibitors (without HDAC6 action) with a proteasome inhibitor on apoptosis of nasopharyngeal carcinoma (NPC). We found that combination of a proteasome inhibitor, bortezomib, and several class I HDAC inhibitors, including MS-275, apicidin and romidepsin, potently induced killing of NPC cells both in vitro and in vivo. Among the drug pairs, combination of bortezomib and romidepsin (bort/romidepsin) was the most potent and could induce apoptosis at low nanomolar concentrations. The apoptosis of NPC cells was reactive oxygen species (ROS)- and caspase-dependent but was independent of HDAC6 inhibition. Of note, bort/romidepsin might directly suppress the formation of aggresome through the downregulation of c-myc. In addition, two markers of endoplasmic reticulum (ER) stress-induced apoptosis, ATF-4 and CHOP/GADD153, were upregulated, whereas a specific inhibitor of caspase-4 (an initiator of ER stress-induced apoptosis) could suppress the apoptosis. When ROS level in the NPC cells was reduced to the untreated level, ER stress-induced caspase activation was abrogated. Collectively, our data demonstrate a model of synergism between proteasome and class I HDAC inhibitors in the induction of ROS-dependent ER stress-induced apoptosis of NPC cells, independent of HDAC6 inhibition, and provide the rationale to combine the more specific and potent class I HDAC inhibitors with proteasome inhibitors for the treatment of cancers.
© 2014 UICC.

Entities:  

Keywords:  class I histone deacetylase inhibitor; endoplasmic reticulum stress; histone deacetylase 6; nasopharyngeal carcinoma; proteasome inhibitor

Mesh:

Substances:

Year:  2014        PMID: 24771510     DOI: 10.1002/ijc.28924

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

Review 1.  HDACs and HDAC Inhibitors in Cancer Development and Therapy.

Authors:  Yixuan Li; Edward Seto
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

Review 2.  Targeting the unfolded protein response in head and neck and oral cavity cancers.

Authors:  Daniel W Cole; Peter F Svider; Kerolos G Shenouda; Paul B Lee; Nicholas G Yoo; Thomas M McLeod; Sean A Mutchnick; George H Yoo; Randal J Kaufman; Michael U Callaghan; Andrew M Fribley
Journal:  Exp Cell Res       Date:  2019-05-07       Impact factor: 3.905

3.  Assessment of HDAC Inhibitor-Induced Endoplasmic Reticulum (ER) Stress.

Authors:  Melisa Halilovic; Lisa Marx-Blümel; Christian Marx; Katrin Buder; James F Beck; Jürgen Sonnemann
Journal:  Methods Mol Biol       Date:  2023

4.  Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.

Authors:  Neale T Hanke; Linda L Garland; Amanda F Baker
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-18       Impact factor: 4.553

5.  Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.

Authors:  Yoichi Imai; Eri Ohta; Shu Takeda; Satoko Sunamura; Mariko Ishibashi; Hideto Tamura; Yan-Hua Wang; Atsuko Deguchi; Junji Tanaka; Yoshiro Maru; Toshiko Motoji
Journal:  JCI Insight       Date:  2016-04-21

6.  Caffeic acid phenethyl ester enhances TRAIL-mediated apoptosis via CHOP-induced death receptor 5 upregulation in hepatocarcinoma Hep3B cells.

Authors:  Matharage Gayani Dilshara; Rajapaksha Gedara Prasad Tharanga Jayasooriya; Sang Rul Park; Yung-Hyun Choi; Il-Whan Choi; Gi-Young Kim
Journal:  Mol Cell Biochem       Date:  2016-06-03       Impact factor: 3.396

7.  Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.

Authors:  Katrin Noack; Nisintha Mahendrarajah; Dorle Hennig; Luisa Schmidt; Florian Grebien; Dagmar Hildebrand; Markus Christmann; Bernd Kaina; Andreas Sellmer; Siavosh Mahboobi; Katharina Kubatzky; Thorsten Heinzel; Oliver H Krämer
Journal:  Arch Toxicol       Date:  2016-11-02       Impact factor: 5.153

8.  Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib.

Authors:  Kwai Fung Hui; Po Ling Yeung; Alan K S Chiang
Journal:  Oncotarget       Date:  2016-01-26

Review 9.  Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.

Authors:  Kwai Fung Hui; Kam Pui Tam; Alan Kwok Shing Chiang
Journal:  Viruses       Date:  2017-11-21       Impact factor: 5.048

10.  The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.

Authors:  Maria Cosenza; Monica Civallero; Stefania Fiorcari; Samantha Pozzi; Luigi Marcheselli; Alessia Bari; Paola Ferri; Stefano Sacchi
Journal:  Cancer Biol Ther       Date:  2016-09-22       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.